Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.6% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s share price traded down 5.6% during trading on Tuesday . The company traded as low as $10.00 and last traded at $9.98. 167,376 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 851,992 shares. The stock had previously closed at $10.57.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on STOK shares. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Price Performance

The firm has a market capitalization of $582.14 million, a price-to-earnings ratio of -5.23 and a beta of 0.95. The firm has a 50 day moving average price of $11.08 and a 200-day moving average price of $12.72.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Equities research analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the sale, the general counsel now owns 21,476 shares in the company, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock valued at $809,421 over the last three months. 11.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently bought and sold shares of the company. Rhumbline Advisers increased its holdings in Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after buying an additional 2,787 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics in the 4th quarter valued at approximately $124,000. Assenagon Asset Management S.A. raised its holdings in Stoke Therapeutics by 2.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after purchasing an additional 38,446 shares during the last quarter. Exome Asset Management LLC purchased a new stake in Stoke Therapeutics during the third quarter worth $2,170,000. Finally, Barclays PLC grew its holdings in Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after purchasing an additional 47,239 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.